Multiplex Antigen Near-Patient Tests in Respiratory Tract Infections

By Staff Writer

November 7, 2023

Understanding Respiratory Tract Infections (RTIs)

RTIs are some of the most common illnesses, causing a significant number of outbreaks annually. Viruses such as SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) are often the culprits. These RTIs lead to a surge in hospital admissions during winter months, and their symptoms can be very similar, making it challenging to differentiate between them.

Multiplex Antigen Near-Patient Tests

Laboratories typically conduct the gold standard for these tests, reverse transcription polymerase chain reaction (RT-PCR). On the other hand, antigen near-patient tests (NPTs) offer quicker, more affordable, and easier testing. These tests can identify many viruses in multiplex tests or just one virus in singleplex tests, but they are less accurate overall. 

For the purpose of managing and identifying RTIs in primary and residential care settings, multiplex antigen NPTs may be helpful. Their viability and effectiveness are still unknown, though. Although the company states that these tests have acceptable diagnostic accuracy, there are questions regarding the sensitivity of these tests. This applies especially to RSV and influenza. This may reduce their usefulness in contexts involving primary or residential care.

The Current State of Affairs

There is limited guidance available on the use of multiplex antigen NPTs. Two international recommendations were identified, one from the Public Health Laboratory Network and Communicable Diseases Network Australia, which did not recommend the use of these tests. Another evaluation report by the Haute Autorité de Santé (HAS) in France found no clear medical benefit to using these tests in primary care settings. The World Health Organisation ACT-Accelerator Transition Plan has supported the development and acceleration of access to affordable COVID-19 rapid antigen diagnostic tests. This highlights potential interest in these and related technologies.

The Road Ahead

Given the uncertainties surrounding the effectiveness and feasibility of multiplex antigen NPTs in primary and residential care facilities, further studies are required. These studies should prospectively assess the diagnostic performance and clinical utility of multiplex antigen NPTs. The goal is to inform public policy on the use of these tests in these settings. Potentially helping to reduce inappropriate antibiotic use or emergency department visits for non-serious infections.

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.